Hostname: page-component-7479d7b7d-767nl Total loading time: 0 Render date: 2024-07-12T05:27:58.178Z Has data issue: false hasContentIssue false
  • English
  • Français

The UK control programme for the haemoglobin disorders

Published online by Cambridge University Press:  10 October 2008

Mary Petrou
Mary Petrou*
Affiliation:
Perinatal Centre, Department of Obstetrics and Gynaecology, University College London Medical School, London, UK
*
Dr Mary Petrou, University College London Medical School, Perinatal Center, Department of Obstetrics and Gynaecology, 86–96 Chenies Mews, London WC1E 6HX, London, UK
Get access Rights & Permissions [Opens in a new window]

Extract

The haemoglobin disorders are a group of recessively inherited conditions of varying severity. In the homozygous state, alpha zero thalassaemia causes hydrops fetalis, beta thalassaemia usually causes a severe transfusion-dependent anaemia and sickle cell anaemia (HbSS), haemoglobin S/C disease, haemoglobin S/D disease and haemoglobin S/beta thalassaemia cause sickling disorders ranging from quite mild to very severe. Haemoglobin disorders are among the commonest inherited diseases in the UK. Management can be very burdensome, but produces good results in many cases. The disorders can also be prevented by a programme of carrier screening, genetic counselling and prenatal diagnosis in populations at risk. The WHO has defined a “haemoglobinopathy control programme” as an integral strategy combining optimal patient care with prevention based on community education, propective carrier diagnosis, genetic counselling and the offer of prenatal diagnosis. The services required for haemoglobin disorders in the UK have recently been reviewed in a report from the Standing Medical Advisory Committee of the Department of Health. This report focuses on genetic counselling and prenatal diagnosis for haemoglobin disorders.

Type
Articles
Information
Fetal and Maternal Medicine Review , Volume 6 , Issue 4 , November 1994 , pp. 191 - 201
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 World Health Organization. Community approaches to the control of hereditary diseases. Report of a WHO advisory group on hereditary diseases. Geneva 3–5 October 1985. Unpublished WHO document HMG|AG|85.10.Google Scholar
2Report of a working party of the Standing Medical Advisory Committee on sickle cell, thalassaemia and other haemoglobinopathies. London: Her Majestry’s Stationery Office, 1994.Google Scholar
3Kan, YW, Golbus, MS, Trecartin, R, Furbetta, M, Cao, A. Prenatal diagnosis of homozygous beta thalassaemia. Lancet 1975; ii: 790–91.Google Scholar
4Alter, BP, Modell, B, Fairweather, DVI, Hobbins, JC, Mahoney, MJ, Frigoletto, FD et al. Prenatal diagnosis of haemoglobinopathies: a review of 15 cases. N Engl J Med 1976; 295: 1437.Google Scholar
5Modell, B, Ward, RHT, Fairweather, DVI. Effect of introducing antenatal diagnosis on the reproductive behaviour of families at risk for thalassaemia major. Br Med J 1980; 2: 737.Google Scholar
6Matsakis, M, Berdoukas, VA, Angastiniotis, M, Mouzounas, M, Ioannou, P, Ferrari, M et al. Haematological aspects of antenatal diagnaosis for thalassaemia in Britain. Br J Haematol 1980; 45: 185–97.CrossRefGoogle Scholar
7Modell, B. EC concerted action on developing patient registers as a tool for improving service delivery for haemoglobin disorders. In: Fracchia, GN, Theophilatou, M eds. Health services research. Amsterdam: IOS Press, 1993.Google Scholar
8Anionwu, EN, Patel, N, Kanji, G, Renges, H, Brosovic, M. Counselling for prenatal diagnosis of sickle cell disease and ²-thalassaemia major: a four year experience. J Med Genet 1987; 25: 769.Google Scholar
9Petrou, M, Brugiatelli, M, Ward, RHT, Modell, B. Factors affecting the uptake of prenatal diagnosis for sickle cell disease. J Med Genet 1992; 29: 820–23.Google Scholar
10Modell, B, Bulyzhenkov, V. Distribution and control of some genetic disorders. WHO Stat Quart 1988; 41: 209–18.Google Scholar
11 World Health Organization. The haemoglobinopathies in Europe. Unpublished WHO document EUR ICP MCH 110 1987.Google Scholar
12Petrou, M, Brugiatelli, M, Old, J, Hurley, P, Ward, RHT, Wong, KP et al. Alpha thalassaemia hydrops fetalis in the UK: the importance of screening pregnant women of Chinese, other South East Asian and Mediterranean extraction for alpha thalassaemia trait. Br J Obstet Gynaecol 1992; 99: 985–89.Google Scholar
13Tillyer, ML, Varawalla, NY, Tillyer, CR, Sandhu, P, Modell, B. Thalassaemias, abnormal haemoglobins and iron deficiency in a British Asian population. Clin Lab Haematol 1993; 15: 157–64.Google Scholar
14Fairweather, DVI, Modell, B, Berdoukas, V, Alter, BP, Nathan, DG, Loukopoulos, D et al. Antenatal diagnosis of thalassaemia major. Br Med J 1978; 1: 350–53.Google Scholar
15Fairweather, DVI, Ward, RHT, Modell, B. Obstetric aspects of mid-trimester fetal blood sampling by needling or fetoscopy. Br J Obstet Gynaecol 1980; 87: 87–99.Google Scholar
16Kanokpongsukdi, S, Ward, RHT, Petrou, M, Modell, B, Fairweather, DVI. Diagnostic fetal blood sampling for the haemoglobinopathies –10 years experience. Eur J Obstet Gynecol 1985; 20: 35–41.Google Scholar
17Old, JM, Petrou, M, Ward, RHT, Karagozlu, F, Modell, B. First trimester fetal diagnosis for haemoglobinopathies: three cases. Lancet 1982; ii: 1413–16.Google Scholar
18Ward, RHT, Modell, B, Petrou, M, Karagozlu, F, Douratzos, E. Method of sampling chorionic villi in first trimester of pregnancy under guidance of real time ultrasound. Br Med J 1983; 266: 1542–44.Google Scholar
19Ward, RHT, Petrou, M, Modell, B, Knott, PD, Maxwell, D, Hooker, JG. Chorionic villus sampling in a high risk population– 4 years experience. Br J Obstet Gynaecol 1988; 95: 1080–85.Google Scholar
20Old, JM, Fitches, A, Heath, CM, Thein, SL, Weatherall, DJ, Warren, R et al. First trimester fetal diagnosis for haemoglobinopathies: report on 200 cases. Lancet 1986; 2: 763–67.Google Scholar
21Old, JM, Petrou, M, Modell, B, Weatherall, DJ. Feasibility of antenatal diagnosis of thalasseamia by DNA polymorphisms in Asian Indian and Cypriot populations. Br J Haematol 1984; 57: 255–63.Google Scholar
22Baysal, E. The ² and ± thalassaemias repository. Haemoglobin 1992; 16: 237.Google Scholar
23Cao, A, Results of programmes for antenatal detection of thalassaemia in reducing the incidence of the disorder. Blood Rev 1987; 1: 169–76.Google Scholar
24Angastiniotis, MA, Kyriakidou, S, Hadjiminas, M. How thalassaemia was controlled in Cyprus. World Health Forum 1986; 7: 291–97.Google Scholar
25Kuliev, A. Thalassaemia can be prevented. World Health Forum 1986; 7: 286–90.Google Scholar
26Modell, B, Petrou, M, Ward, RHT, Fairweather, DVI, Rodeck, C, Varnavides, LA et al. Effect of fetal diagnosis testing on birth rate of thalassaemia major in Britain. Lancet 1984; 2: 1383–86.Google Scholar
27Darr, A. The social implications of thalassaemia among Muslims of Pakistani origin in England – family experience and service delivery. PhD, University of London1990.Google Scholar
28 Royal College of Physicians. Prenatal diagnosis and genetic screening: community and service implications. Report of the Royal College of Physicians of London, September 1989.Google Scholar